SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced two major initiatives to make FDA-approved GLP-1 medications more ...
GoodRx will pay $25 million to settle claims it shared users’ sensitive data with third parties like Meta and Google without consent. FTC found violations of federal law, including the Health Breach ...
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on GoodRx Holdings (NASDAQ:GDRX) in the last three months. The following table encapsulates their ...
GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid ...
GoodRx for Weight Loss, a direct-to-consumer telemedicine subscription is designed to simplify and manage every step of the GLP-1 treatment journey, from initial consultation to prescription ...
Downgrading GoodRx to a sell rating on recent decline fundamentals. GoodRx's revenue growth is decelerating, with significant reliance on retail partnerships and cyclical transactional revenue, making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results